New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - terazosin hydrochloride dihydrate 1.19mg equivalent to 1 mg terazosin;   - tablet - 1 mg - active: terazosin hydrochloride dihydrate 1.19mg equivalent to 1 mg terazosin   excipient: lactose monohydrate magnesium stearate maize starch purified talc - terazosin tablets are indicated for the symptomatic and pathophysiologic treatment of benign prostatic hyperplasia (bph) when: - prostatectomy is not indicated - patient is not fit for surgery - elective surgery must be postponed (e.g., waiting list) - patient refuses surgical treatment. terazosin is also indicated in the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - terazosin hydrochloride dihydrate 2.38mg equivalent to 2 mg terazosin;   - tablet - 2 mg - active: terazosin hydrochloride dihydrate 2.38mg equivalent to 2 mg terazosin   excipient: lactose monohydrate magnesium stearate maize starch purified talc quinoline yellow - terazosin tablets are indicated for the symptomatic and pathophysiologic treatment of benign prostatic hyperplasia (bph) when: - prostatectomy is not indicated - patient is not fit for surgery - elective surgery must be postponed (e.g., waiting list) - patient refuses surgical treatment. terazosin is also indicated in the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - terazosin hydrochloride dihydrate 5.95mg equivalent to 5 mg terazosin;   - tablet - 5 mg - active: terazosin hydrochloride dihydrate 5.95mg equivalent to 5 mg terazosin   excipient: iron oxide red lactose monohydrate magnesium stearate maize starch purified talc - terazosin tablets are indicated for the symptomatic and pathophysiologic treatment of benign prostatic hyperplasia (bph) when: - prostatectomy is not indicated - patient is not fit for surgery - elective surgery must be postponed (e.g., waiting list) - patient refuses surgical treatment. terazosin is also indicated in the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - terazosin hydrochloride dihydrate 1.19mg equivalent to 1 mg terazosin - tablet - 1 mg - active: terazosin hydrochloride dihydrate 1.19mg equivalent to 1 mg terazosin excipient: lactose magnesium stearate microcrystalline cellulose starch

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - terazosin hydrochloride dihydrate 2.38mg equivalent to terazosin 2 mg - tablet - 2 mg - active: terazosin hydrochloride dihydrate 2.38mg equivalent to terazosin 2 mg excipient: lactose magnesium stearate microcrystalline cellulose quinoline yellow starch sunset yellow aluminium lake - latest regulatory activity

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - terazosin hydrochloride dihydrate 5.95mg equivalent to terazosin 5 mg - tablet - 5 mg - active: terazosin hydrochloride dihydrate 5.95mg equivalent to terazosin 5 mg excipient: ferrosoferric oxide iron oxide red lactose magnesium stearate microcrystalline cellulose starch

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - terazosin hydrochloride dihydrate 2,375 mg - eq. terazosin 2 mg - tablet - 2 mg - terazosin hydrochloride - terazosin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - terazosin hydrochloride dihydrate 5,935 mg - eq. terazosin 5 mg - tablet - 5 mg - terazosin hydrochloride - terazosin

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - terazosin hydrochloride (unii: d32s14f082) (terazosin - unii:8l5014xet7) - terazosin 1 mg - terazosin capsules, usp are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules, usp. the long-term effects of terazosin capsules, usp on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin capsules, usp are also indicated for the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

Canada - English - Health Canada

abbott laboratories, limited - terazosin (terazosin hydrochloride); terazosin (terazosin hydrochloride); terazosin (terazosin hydrochloride) - kit - 1mg; 2mg; 5mg - terazosin (terazosin hydrochloride) 1mg; terazosin (terazosin hydrochloride) 2mg; terazosin (terazosin hydrochloride) 5mg - alpha-adrenergic blocking agents